Gene therapy specialist AskBio Inc, a wholly owned and independently operated subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009.
The product is an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease.
With this announcement, the AB-1009 programme progresses to Phase 1/2 and AskBio will commence a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting the first patient in early 2026.
In September 2024, AskBio formed a strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. BBM granted AskBio a sublicence to use the proprietary AAV capsid in the AB-1009 programme and provided AAV vector production services.
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
ElpasBio partners with Fosun Kairos on AlloJoin stem cell therapy
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
WuXi Biologics granted UK GMP certification for two manufacturing facilities in Wuxi
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer